BioXcel Therapeutics (BTAI) reported Q3 EPS of ($1.49), $0.17 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $1.12 million.
BioXcel Therapeutics (BTAI) reported Q3 EPS of ($1.49), $0.17 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $1.12 million.